The FDA will hold an advisory committee meeting in September to review Grail’s Galleri multi-cancer early detection test after the product failed to meet the primary endpoint in a large, randomized trial conducted in the UK. The agency’s decision to convene the panel reflects the continued scrutiny around evidence strength and clinical benefit for MCED technology. Grail has been in an iterative review process with the FDA, while also reporting revenue growth tied to ongoing study activity and market expectations. The advisory committee outcome is not the final decision, but it can shape how the agency interprets endpoint relevance and performance thresholds. For payors and health systems, the panel becomes a timing catalyst: FDA approval is frequently treated as the “gate” for broader coverage consideration, particularly as employers and insurers watch for confirmatory evidence.